Intact Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Intact Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,800	Closed	-$425K	–	257
2023 Q3	$425K	Hold	4,800	–	–	0.02%	229
2023 Q2	$416K	Buy	+4,800	New	+$452K	0.02%	233
2016 Q4	–	Sell	-4,000	Closed	-$370K	–	270
2016 Q3	$370K	Hold	4,000	–	–	0.01%	217
2016 Q2	$311K	Hold	4,000	–	–	0.01%	229
2016 Q1	$330K	Buy	4,000 +1,200	+43%	+$97.6K	0.01%	220
2015 Q4	$293K	Hold	2,800	–	–	0.01%	213
2015 Q3	$295K	Hold	2,800	–	–	0.01%	208
2015 Q2	$383K	Sell	2,800 -1,300	-32%	-$161K	0.02%	206
2015 Q1	$511K	Sell	4,100 -600	-13%	-$63.6K	0.02%	206
2014 Q4	$425K	Hold	4,700	–	–	0.02%	232
2014 Q3	$339K	Hold	4,700	–	–	0.01%	234
2014 Q2	$292K	Hold	4,700	–	–	0.01%	222
2014 Q1	$321K	Hold	4,700	–	–	0.01%	219
2013 Q4	$330K	Buy	4,700 +1,000	+27%	+$67.9K	0.02%	191
2013 Q3	$267K	Buy	+3,700	New	+$246K	0.01%	196

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Intact Investment Management's BMRN Position: Q4 2023 in Review

Intact Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 4,800 shares — an estimated $425K sold.

Intact Investment Management first reported a position in BMRN in Q3 2013 and held it in 15 quarters. The position peaked at $511K in Q1 2015. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

Intact Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Intact Investment Management sold 4,800 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $425K.
Intact Investment Management first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 15 quarters.
Intact Investment Management's BioMarin Pharmaceuticals position peaked at $511K in Q1 2015.
547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Intact Investment Management's 13F filing for Q4 2023, filed 5 Feb 2024.